Correspondence

Angiomyofibroblastoma of the vagina

Angiomyofibroblastoma is a rare, recently described, soft tissue tumour that occurs mainly, but not exclusively, in the vulval region of premenopausal women.1 We report a case arising in the vagina to draw the attention of pathologists to the fact that this rare neoplasm can occur outside the vulva.

A 54 year old woman, para 4 + 0, presented with a two year history of vaginal wall prolapose. Vaginal examination revealed a polyloid lesion on the anterior wall. Surgical removal and vaginal wall repair was performed.

The surgical specimen consisted of surface mossa with an underlying well circumscribed, firm, homogenous, white coloured lesion measuring 2.5 cm in maximum diameter. Histology showed unremarkable surface squamous epithelium. Deep to this, a well circumscribed but unencapsulated lesion was present. This contained numerous randomly distributed blood vessels, most of which were thin walled and capillary-like (fig 1A), whereas others had thick muscular walls. The surrounding stroma contained spindle shaped cells, some with wavy nuclei (fig 1B), and others with a plasmacytoid or epithelioid appearance. Occasional multinucleate cells were present (fig 1B). There was little or no nuclear pleomorphism and mitotic figures were not identified. In some areas there was a tendency for concentration of the stromal cells around blood vessels, although this was not a prominent feature. The stroma contained collagen fibres and was focally oedematous with some extravasation of red blood cells. Immunohistochemical staining showed diffuse positivity of stromal cells for vimentin (Dako, Copenhagen, Denmark). There was focal strong staining for desmin (Dako) and occasional cells were weakly positive for α smooth muscle actin (Sigma, Poole, Dorset, UK). There was no staining of stromal cells for S100 protein (Diagnostic Products Ltd, Abingdon, UK), AE1/AE3 (Dako), CD34 (Sero-tec, Oxford, UK), or factor VIII related antigen (Signet, Ontario, Canada). Staining for α smooth muscle actin, CD34, and factor VIII highlighted the vascular channels. There was diffuse strong positivity of stromal cells for the oestrogen receptor (ER) (Dako) and progesterone receptor (PR) (Dako).

Within the vulva the chief differential diagnosis of angiomyofibroblastoma is likely to be aggressive angiomyxoma. Angiomyofibroblastoma is distinguished from aggressive angiomyxoma by its circumscribed border and higher cellularity, by the frequent presence of plump stromal cells, and by a lesser degree of stromal myxoid change. Angiomyofibroblastoma of the vulva is almost always a benign lesion which, unlike aggressive angiomyxoma, shows little or no tendency for local recurrence. However, a single case with sarcormatos transformation has been described.4

Since the original description, angiomyofibroblastoma has been described outside the vulva, in the female urethra and in the male genital tract, and there have been occasional reports of this neoplasm arising in the vagina.5 In a report of 12 angiomyofibroblas-

Figure 1 (A) Numerous capillary-like vascular channels are present within the neoplasm. (B) The stroma contains spindle shaped cells with occasional multinucleate cells.

W G McCluggage
Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BL, Northern Ireland

R G Whittie
Department of Obstetrics and Gynaecology, Mater Infirmorum Hospital Trust, Belfast BT14 6AB, Northern Ireland

Thrombophilia testing

In his recent leader, Dr Baglin gives an interesting overview of thrombophilia testing. However, his clinical practice of screening all unselected patients with an episode of venous thromboembolism is at odds with the British committee for guidelines in haematology guidelines on the investigation of thrombophilia.2 According to these guidelines, the main indications for thrombophilia testing are patients with a venous thromboembolism before the age of 45 years, recurrent venous thrombosis or thrombophlebitis, thrombosis in an unusual site, or a first venous thromboembolism with a clear family history of venous thrombosis. Such restrictions on expensive and time consuming thrombophilia tests to patient groups more likely to have underlying thrombophilic defects are almost mandatory.3 Haematology departments working under the financial constraints of the present day national health service.

P T Murphy
Department of Haematology, Royal Shrewsbury Hospital, Shrewsbury SY3 8QX, UK

1 Baglin T. Thrombophilia testing: what do we think the tests mean and what should we do with the results? J Clin Pathol 2000;53:703-9.

A comparison of international normalised ratio (INR) measurement in hospital and general practice settings: evidence for lack of standardisation

Previous reports of discrepancies in international normalised ratio (INR) measurement between centres have focused on hospital based methodologies.4,5 Previously, we have demonstrated differences in derived INR values for the same sample tested in primary care and in one of three different haematology laboratories.4 However, this study is an extension of the previous one, investigating comparative results based on contemporaneous samples measured in one primary care centre and in two hospital laboratories using a variety of techniques.

Venous blood was drawn from patients in one primary care centre over a three month period. The sample was tested on site for INR estimation using the Portico thrombostest NPT and Thrombostent reagent. The reagent of the venous sample was placed in a citrated collection bottle and sent to two reference laboratories routinely used by the general practitioner to measure INR values (laboratories 1 and 2). Laboratory 1 determined INR values using three separate methods: a Thrombostent using Thrombostent, an ACL machine using IL reagent, and a KC-10 machine using Manchester reagent. Laboratory 2 determined INR values using a KC-10 machine with Manchester reagent. Because laboratory 1 acts as the regional reference laboratory and uses the ACL/IL combination as its routine


www.jclinpath.com
The rate of unnecessary warfarin dose adjustment is maintained for individual patients, with continuity of INR estimation by location and derived INR using the same technology. This practice derived INR and the laboratory centre monitors their INR. Nevertheless, the ent doses of warfarin depending upon which settings. The clinical implication of these associated with INR measurement in different systems. Furthermore, there was a significant difference between ACL and KC-10 results from the same laboratory and between KC10 results from different laboratories.

Our results suggest that regular differences occur in INR measurements obtained on the same samples using different methodologies and draws attention to inherent problems associated with INR measurement in different settings. The clinical implication of these findings is that patients could receive different doses of warfarin depending upon which centre monitors their INR. Nevertheless, the best agreement to be found was between the practice derived INR and the laboratory derived INR using the same technology. This shows that routine care INR estimations are as reliable as laboratory estimations using the same combination of reagents and technology.

Therefore, it follows that as long as continuity of INR estimation by location and method is maintained for individual patients, the rate of unnecessary warfarin dose adjustment will be reduced.

We have described the transition of the INR method of INR testing, the result obtained was taken as the gold standard. Samples were sent to the laboratory using routine transport with no samples tested more than 12 hours after venesection.

Fifty four separate venous samples from 26 patients were sent from the practice to the laboratories. The INR values obtained ranged from 1.0 to 6.1. Table 1 shows the mean difference in results from the various machines. There was a significant mean difference in the practice Thorotrac results relative to the ACL and the KC-10 in both laboratories, but none between practice measurements and those obtained in laboratory using the same technology. There were also significant differences between all hospital systems. Furthermore, there was a significant difference between ACL and KC-10 results from the same laboratory and between KC10 results from different laboratories.

Our results suggest that regular differences occur in INR measurements obtained on the same samples using different methodologies and draws attention to inherent problems associated with INR measurement in different settings. The clinical implication of these findings is that patients could receive different doses of warfarin depending upon which centre monitors their INR. Nevertheless, the best agreement to be found was between the practice derived INR and the laboratory derived INR using the same technology. This shows that routine care INR estimations are as reliable as laboratory estimations using the same combination of reagents and technology. Therefore, it follows that as long as continuity of INR estimation by location and method is maintained for individual patients, the rate of unnecessary warfarin dose adjustment will be reduced.

Table 1 Mean difference (SEM) in INR between methods (n = 54)

<table>
<thead>
<tr>
<th>Method</th>
<th>ACL Lab 1</th>
<th>KC-10 Lab 1</th>
<th>KC10 Lab 2</th>
<th>Thorotrac</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACL Lab 1</td>
<td>0.25 (0.04)*</td>
<td>0.50 (0.05)**</td>
<td>0.35 (0.06)**</td>
<td>-0.06 (0.04)</td>
</tr>
<tr>
<td>KC-10 Lab 1</td>
<td>0.24 (0.03)**</td>
<td>0.11 (0.05)*</td>
<td>-0.13 (0.06)*</td>
<td>-0.55 (0.07)**</td>
</tr>
<tr>
<td>KC-10 Lab 2</td>
<td>-0.42 (0.07)**</td>
<td>-0.42 (0.07)**</td>
<td>-0.42 (0.07)**</td>
<td>-0.42 (0.07)**</td>
</tr>
</tbody>
</table>

* p < 0.05; ** p < 0.001.

INR, international normalised ratio.

More fundamental questions are: What is the purpose of giant multiauthor texts like this, who needs them, when will they be used and how, and if they are required, what is the "pecking order" for choice of these? Very often better written, more detailed, and more up to date descriptions exist in more specific texts. The constraints of producing a multi author work like this mean that the individual chapters are unlikely to rival the detail of the specialised book. However, I suspect most of us consult books like this on the areas in which we do not have specialised texts. Apart from this text, this market segment appears to include Ackerman's Surgical Pathology edited by Rosai, Anderson's Pathology edited by Damjanov and Linder, and Silverberg's Principles and Practice of Surgical Pathology. Perhaps the Oxford Textbook of Pathology is not a direct competitor because its remit is so different. The choice of which of these books to consult is a personal matter, depending on preferred style and balance of writing. In my view, Ackerman is particularly commendable for Rosai, masterful talking about how the diagnosis in surgical pathology, Silverberg is brief and to the point, yet quite detailed, and Anderson's Pathology is good for clinicopathological correlations and the general context of disease. This text lies somewhere in the middle, meeting several of the purposes, but to my mind it is beaten for quality of histological description by the first two works, although still very worthwhile if funds allow its purchase.

T J STEPHENSON


The Atlas of Immunology aims to be "the most up to date and thoroughly illustrated treatise available". Sadly the book does not achieve what it sets out to do. Many of the images by their nature attempt to illustrate clinical or clinical laboratory situations and, particularly for these, the highest quality of image is required to enable the differentiation from other often subtly different conditions. Many clinical images are given simply as line drawings—for example, a malar rash in systemic lupus erythematosis, the hands in systemic sclerosis, or a baby with an intra-venous line (the image for soro-containing and immune deficiency). A dermatology text would not accept line drawings of a malar rash and why should immunologists? It is as if a team of journalists have collected as many images as possible regardless of quality, content, or currency. All are printed in black and white, and the reproduction is often poor. No explanation is given to any figure, either in the text, or in the legends, which are all simple statements such as "release of sequestered antigen". For images such as indirect immuno-fluorescence of salivary gland duct showing the staining pattern of anti-salivary gland antibodies labelled simply as "Syögren's syndrome" this is especially uninformative. Even the accompanying text is now largely outdated.

This ambitious project was an opportunity for two distinguished authors to provide the reader with access to a lifetime's collection of the distinguishing features, and contrasting it with similar images. As a minimum it would be useful.
use colour, and preferably would be on CD-ROM and have internet links to images so that they could be incorporated into teaching material. This opportunity has been missed.

W A C SEWELL


With the dramatic fall in professors of medical microbiology, together with the recommended reduction in didactic teaching of medical students, the requirement for a readable and affordable textbook assumes even more importance. Although the would be doctors of tomorrow do not necessarily see it like that—plenty of money for the pleasures of life, but none for books. David Shanson’s Microbiology in Clinical Practice has been a recommended text for medical students throughout the UK since its launch in 1982. So what has changed since the first edition? New diseases and new pathogens have emerged such as Helicobacter pylori; hepatitis C, E, and G; Shigella flexneri; and variant CJD—to name but a few. In addition to the new, we welcome back old: diphtheria and tuberculosis. The ever ingenious bacteria appear to have the upper hand against the pharmacuetical chemist, and the global epidemic of AIDS marches ever onwards, ever confident into this new millennium. In an attempt to aid the would be Alexander Flemings of the future to climb out of their Petri dishes and discard the loop, an additional chapter entitled “Applications of molecular biology to clinical microbiology and infectious diseases” has been added. This highly readable textbook is recommended to medical students, MLSOs, infection control nurses, and general practitioners alike. Value for money at £29.99—all for the price of a few beers!

R C SPENCER


This is the fourth edition of this excellent book, which has found on the shelves of most microbiology laboratories in the UK. In the 16 years since the first edition it has grown from 13 to 19 chapters to take account of recent developments in infections and agents such as new variant CJD, risk assessment, and European regulations and recommendations.

The book is full of practical advice on avoiding laboratory hazards, such as aerosol generation and sharps injury, as relevant now as in 1982. The book is also a comprehensive reference and test formats. It also provides a fascinating list of published reports of laboratory-acquired infections and is the standard UK reference source for these.

The strength of this book lies in its detailed coverage of all aspects of laboratory practice and management, which is backed up by reference to appropriate health and safety regulations or guidelines. For example, there is an excellent comprehensive chapter on safety cabinets and a helpful section on instrument maintenance.

E J KUIPERS


In the past decade, proton pump inhibitors have dramatically changed the treatment of acid related disorders. They profoundly suppress gastric acid, without the development of tolerance or side effects, and are very commonly used. As such, this book edited by Dr Olbe is of interest to clinicians, physiologists, and pharmacists. The book is written by experts in the field and largely consists of two sections on pharmacology and clinical effects. The first section covers among others the mechanism of action and the consequences of acid inhibition in animals and humans. The second section focuses on the use of proton pump inhibitors for ulcer disease, Zollinger-Ellison syndrome, and gastro-oesophageal reflux disease. Thus, the book deals with many topics. Unfortunately, the subject index is limited, which hampers its use as a quick reference. Furthermore, several currently relevant issues are not, or only briefly, discussed. These include the new formulation of omeprazole in a multiple pellet solution, the use of intravenous formulations for upper gastrointestinal bleeding, the possibility of nocturnal acid breakthrough and fundic gland polyp formation during treatment, as well as that of rebound hypersecretion after the withdrawal of treatment. Finally, the topic of Helicobacter pylori and atrophic gastritis is discussed repeatedly, but only some of the arguments mentioned in the international literature are brought forward.

Therefore, a second edition of the book would benefit from such updating for clinicians who are interested in the newest aspects of proton pump inhibitor treatment.

Calendar of events

Full details of events to be included should be sent to Maggie Butler, Technical Editor JCP, The Cedars, 36 Queen Street, Castle Hillingham, Essex CO9 3HA, UK; email: maggiebutler@gilotree.prestel.co.uk

Applications and Techniques in Veterinary Pathology
5 October 2000, Royal College of Pathologists, London, UK
Further details: Maureen Russell, Scientific Meetings Officer, Royal College of Pathologists, 2 Carlton House Terrace, London SW1Y 5AF, UK; (Tel +44 (0)20 7451 6740; email www.rcpath.org)

New Millenium Bugs
18 October 2000, Royal College of Pathologists, London, UK
Further details: Maureen Russell, Scientific Meetings Officer, Royal College of Pathologists, 2 Carlton House Terrace, London SW1Y 5AF, UK. (Tel +44 (0)20 7451 6740; email www.rcpath.org)

Practical Adult Cardiovascular Pathology Course
6–8 November 2000, Royal Brompton Hospital, Imperial School of Medicine, National Heart and Lung Institute
Further details: Short Course Office, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK. (Tel +44 (0)20 7351 8172; fax +44 (0)20 7351 8246; email shortcourse.NHLI@ICAC.UK)

Practice Guidelines for Non-Hodgkin’s Lymphoma
21–22 November 2000, Royal College of Pathologists, London, UK
Further details: Maureen Russell, Scientific Meetings Officer, Royal College of Pathologists, 2 Carlton House Terrace, London SW1Y 5AF, UK. (Tel +44 (0)20 7451 6740; email www.rcpath.org)

Cytopathology Update: Making Cervical Cytopathology Work
7 December 2000, Royal College of Pathologists, London, UK
Further details: Maureen Russell, Scientific Meetings Officer, Royal College of Pathologists, 2 Carlton House Terrace, London SW1Y 5AF, UK. (Tel +44 (0)20 7451 6740; email www.rcpath.org)

Diagnostic Gynaecological Pathology
13–15 January 2001, The Embassy Suites, Palm Desert, California, USA
Further details: Department of Continuing Education, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. (Tel +1 617 432 1525; fax +1 617 432 1562; email hms-cme@hms.harvard.edu)

Urological Surgical Pathology for the Practising Pathologist
24–26 March 2001, Sanibel Harbour Resort and Spa, Fort Myers, Florida, USA
Further details: Department of Continuing Education, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. (Tel +1 617 432 1525; fax +1 617 432 1562; email hms-cme@hms.harvard.edu)

6th European Forum on Quality Improvement in Health Care
29–31 March 2001, Bologna, Italy
Further details: BMA/BMJ Conference Unit, BMA House, Tavistock Square, London WC1H 9JR, UK. (Tel +44 (0)20 7383 6409; fax +44 (0)20 7383 6869; email Quality@bma.org.uk; website www.quality.bmj.org)
Best Practice articles (formerly “Broadsheets”) prepared by the Association of Clinical Pathologists

Just published
162 The histological reporting of melanoma 2000 E CALONJE
161 Examination of lung specimens 2000 AR GIBBS, RL ATTANOOUS
160 Renal biopsy specimens 2000 PN FURNESS
159 Examination of large intestine resection specimens 2000 SH BURROUGHS, GT WILLIAMS
158 Neuropathology 2000 WR TIMPERLEY
157 Guidelines for the laboratory handling of laryngectomy specimens 2000 TR HELLWELL
156 Handling oesophageal biopsies and resection specimens and their reporting 2000 NBN IBRAHIM

Recent Publications
155 Pathological investigation of deaths following surgery, anaesthesia, and medical procedures 1999 RD START, SS CROSS
154 Helicobacter pylori 1999 CAM MCNULTY, JI WYATT (with correction in June issue)

Other Best Practice articles are still available for purchase
153 The laboratory investigation of vaginal discharge 1998 KF MACSWEEN, GL RIDGWAY
152 Clinical implications of plasma homocysteine measurement in cardiovascular disease 1998 RA STILL, IW MCDOWELL
151 Investigation of dyslipidaemias 1997 AF WINDER, W RICHMOND, DT VALLANCE
150 Antenatal serological testing and prevention of haemolytic disease of the newborn 1997 JKM DUGUID
149 Serological diagnosis of gluten sensitive enteropathy 1996 DJ UNSWORTH
148 Laboratory diagnosis of malaria 1996 DC WARHURST, JE WILLIAMS
147 Mycological techniques 1996 KG DAVEY, CK CAMPBELL, DW WARNOCK
146 Macroscopic examination of prostatic specimens 1995 P HANINDEN, MC PARKINSON

Earlier Broadsheets may still be available from the author. A full list can be obtained from the Publications Secretary, Association of Clinical Pathologists, 189 Dyke Road, Hove, East Sussex BN3 1TL.

Prices
INLAND One copy, £2.50; 2–10 copies (of any one broadsheet or reprint), £2.00 each; 11–100 copies (of any one), £1.75 each; 101 plus copies (of any one), price to be agreed; authors (over 50 free copies), £1.25 each.
OVERSEAS One copy, $6.75; 2–10 copies (of any one broadsheet or reprint), $5.25; 11–100 copies (of any one), $3.75; 101 plus copies (of any one), price to be agreed.
Authors $2.25. Prices include postage but air mail will be charged extra. Trade discount 10%. All orders (and all changes of address of regular subscribers) should be sent to the Publishing Manager, Journal of Clinical Pathology, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR.